ImmunityBio, Inc.
IBRX
$2.51
$0.041.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 74.65% | 10.31% | 2.40% | -15.27% | -115.67% |
| Total Depreciation and Amortization | -9.33% | -2.84% | -5.89% | -2.69% | -12.67% |
| Total Amortization of Deferred Charges | -29.66% | -45.88% | -52.54% | -51.90% | -35.53% |
| Total Other Non-Cash Items | -118.37% | -1,491.37% | -41.96% | 276.45% | 1,592.11% |
| Change in Net Operating Assets | 57.89% | -43.51% | -40.80% | -114.07% | -290.73% |
| Cash from Operations | 26.14% | -13.00% | -25.79% | -26.89% | -27.05% |
| Capital Expenditure | 73.46% | 50.80% | 91.51% | 85.04% | 57.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.06% | 781.24% | -64,984.62% | -61,258.93% | 27,478.38% |
| Cash from Investing | 337.26% | 516.05% | -498.44% | -319.87% | 111.90% |
| Total Debt Issued | -100.00% | -51.28% | -- | -- | 287.47% |
| Total Debt Repaid | 100.00% | -15.79% | -10.53% | -10.53% | -11.11% |
| Issuance of Common Stock | 1,051.35% | -60.23% | 284.52% | -70.23% | -84.52% |
| Repurchase of Common Stock | 48.59% | 79.58% | -726.67% | -983.19% | -613.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -46.68% | -93.44% | 242.98% | -86.70% | 82.41% |
| Foreign Exchange rate Adjustments | 74.07% | 1,200.00% | 220.00% | 84.65% | -116.77% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -63.87% | -113.49% | 93.48% | -719.42% | 18,127.08% |